EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors

Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani und 5 weitere

TH Open · 01.04.2024 · 08 (02) · e209-e215

DOI: 10.1055/a-2306-0804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift TH Open, erschienen am 01.04.2024. Verfasst von Mark Goldin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Pharmaceuticals, Broxmeyer Fellowship in Clinical Thrombosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.

Methods

We retrospectively studied patients at a 23-hospital system who received andexanet from November 2019 to March 2023. Abstractors coded demographics, comorbidities, anticoagulant use, andexanet indication, and process times. The primary outcome was presentation-to-andexanet time; diagnosis, ordering, and administration times were calculated. Secondary outcomes included in-hospital postandexanet major thromboembolism/bleeding and mortality.

Results

In total, 141 patients were analyzed. Andexanet indications were predominantly neurologic bleeding (85.8%). Twenty-four patients (17.0%) were transferred from nontertiary/academic centers to tertiary/academic centers. The median presentation-to-administration time was 192.5 minutes (interquartile range [IQR]: 108.0–337.0 minutes). Components were as follows: 72.5 minutes (IQR: 39.0–137.5 minutes) for bleeding diagnosis; 35.5 minutes (IQR: 0–96.5 minutes) for andexanet ordering; and 53.0 minutes (IQR: 38.5–78.5 minutes) for administration, which was longer at tertiary/academic hospitals (ratio 1.5, 95% confidence interval [CI]: 1.2–2.0, p = 0.002). Gastrointestinal or other critical bleeding (ratio 2.59, 95% CI: 1.67–4.02, p < 0.001), and tertiary/academic center treatment (ratio 1.58, 95% CI: 1.15–2.18, p = 0.005), were associated with increased time. Major thromboembolism, bleeding, and mortality occurred in 10.6, 12.0, and 22.9% of patients, respectively.

Conclusions

In our cohort, the median presentation-to-administration time was over 3 hours. Cumulative times were longer at tertiary/academic hospitals and for gastrointestinal/other bleeding. Postandexanet major thromboembolism/bleeding occurred more at tertiary/academic hospitals, possibly related to transfers. Prospective studies may elucidate clinical decision-making bottlenecks.

Schlagwörter

Stichwörter der Autor:innen

DOACandexanet alfaclinical pathwaycritical bleedingthromboembolism

Autor:innen und Institutionen

  • Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States.
  • Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States.
  • Department of Medicine, Lenox Hill Hospital at Northwell Health, New York, New York, United States.
  • Biostatistics Unit, Office of Academic Affairs, Northwell Health, Hempstead, New York, United States.
  • Department of Medicine, North Shore University Hospital, Manhasset, New York, United States.
  • Clinical Pharmacy, Long Island Jewish Medical Center, New Hyde Park, New York, United States.

ORCID-Profile: Alex C Spyropoulos

Förderung

  • AstraZeneca Pharmaceuticals
  • Broxmeyer Fellowship in Clinical Thrombosis

Zitieren

APA

Goldin, M., Smith, K., Koulas, I., Leung, T., Ravi, M., Parhar, S., Shah, S., Floyd, K., Ohanesian, L., Bain, R., Defonte, D., Ochani, K., Lin, A., Patel, B., Tsaftaridis, N., Jnani, J., & Spyropoulos, A. C. (2024). Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors. TH Open, 08(02), e209-e215. https://doi.org/10.1055/a-2306-0804

Vancouver

Goldin M, Smith K, Koulas I, Leung T, Ravi M, Parhar S, et al. Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors. TH Open. 2024;08(02):e209-e215. doi:10.1055/a-2306-0804

BibTeX
@article{Goldin2024,
  author = {Goldin, Mark and Smith, Kolton and Koulas, Ioannis and Leung, Tungming and Ravi, Mayuri and Parhar, Sanjit and Shah, Sejal and Floyd, Kayla and Ohanesian, Lori and Bain, Rachel and Defonte, Daniella and Ochani, Kanta and Lin, Amanda and Patel, Bhumi and Tsaftaridis, Nikolaos and Jnani, Jack and Spyropoulos, Alex C},
  title = {Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors},
  journal = {TH Open},
  year = {2024},
  volume = {08},
  number = {02},
  pages = {e209--e215},
  doi = {10.1055/a-2306-0804}
}
Kostenlos starten →